What is Zacks Research’s Estimate for STERIS Q3 Earnings?

STERIS plc (NYSE:STE) – Zacks Research raised their Q3 2025 EPS estimates for shares of STERIS in a note issued to investors on Tuesday, December 24th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.30 for the quarter, up from their previous forecast of $2.29. The consensus estimate for STERIS’s current full-year earnings is $9.10 per share. Zacks Research also issued estimates for STERIS’s Q4 2025 earnings at $2.60 EPS, FY2025 earnings at $9.07 EPS, Q1 2026 earnings at $2.25 EPS, Q3 2026 earnings at $2.50 EPS, FY2026 earnings at $9.92 EPS, Q1 2027 earnings at $2.47 EPS and FY2027 earnings at $10.25 EPS.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. The firm had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.03 EPS.

Several other research analysts have also recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday, November 8th. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Stephens reissued an “overweight” rating and set a $260.00 price target on shares of STERIS in a research report on Thursday, November 7th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Monday, November 18th. Finally, Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, STERIS has an average rating of “Moderate Buy” and an average target price of $262.50.

STERIS Trading Up 0.0 %

Shares of STERIS stock opened at $208.72 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. STERIS has a 52 week low of $197.82 and a 52 week high of $248.24. The stock has a 50 day moving average price of $217.81 and a two-hundred day moving average price of $226.23. The stock has a market capitalization of $20.60 billion, a PE ratio of 47.65 and a beta of 0.83.

Hedge Funds Weigh In On STERIS

A number of large investors have recently bought and sold shares of STE. Franklin Resources Inc. increased its stake in shares of STERIS by 171.2% in the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock worth $191,370,000 after buying an additional 529,308 shares during the period. Tidal Investments LLC grew its holdings in STERIS by 21.0% in the 3rd quarter. Tidal Investments LLC now owns 12,650 shares of the medical equipment provider’s stock worth $3,068,000 after acquiring an additional 2,193 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of STERIS in the third quarter valued at about $9,949,000. World Investment Advisors LLC bought a new position in shares of STERIS during the third quarter valued at about $5,171,000. Finally, SkyView Investment Advisors LLC boosted its holdings in shares of STERIS by 1.6% during the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock worth $765,000 after purchasing an additional 51 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.14% of the company’s stock.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th were paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.09%. The ex-dividend date was Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.